Moderna says its coronavirus vaccine shows promising results in small trial of elderly patients

The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Source: CNBC

By Berkeley Lovelace Jr.@BERKELEYJR

KEY POINTS

  • The vaccine was tested on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, Moderna said.
  • Each participant received two 100 microgram doses of the vaccine 28 days apart.
  • The vaccine produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and killer T-cells, Moderna said.

Moderna’s potential coronavirus vaccine generated a promising immune response in elderly patients in an early stage clinical trial, the biotech firm announced Wednesday.

The company tested its vaccine on 10 adults between the ages of 56 and 70 and 10 elderly adults aged 71 and older, Moderna said. Each participant received two 100 microgram doses of the vaccine 28 days apart.

The volunteers produced neutralizing antibodies, which researchers believe are necessary to build immunity to the virus, and killer T-cells, Moderna said in its results, which have not yet been published in a peer-reviewed journal. Additionally, the antibodies that were produced were higher than those seen in people who have recovered from Covid-19. 

The vaccine also appeared to be well tolerated, with no serious adverse events reported, the company said. Some patients reported fatigue, chills, headaches and pain at the injection site, though the majority of symptoms resolved within two days, the company said. 

Shares of Moderna were up more than 4% in intraday trading Wednesday. The company will hold a conference call at 4:30 p.m. ET to discuss the results.

The vaccine from Moderna is one of several in development to fight the coronavirus, which has infected more than 23.9 million people worldwide and killed at least 820,100, according to data compiled by Johns Hopkins University. There are more than 170 vaccines in development worldwide, according to the World Health Organization. At least 31 are in clinical trials, the WHO said.

Read further

Dr. Zia H Shah, Chief Editor of the Muslim Times

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

For the latest health news from BBC, Please click here

Novavax starting human trial of its vaccine in Australia

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters

DAILY NEW CASES AND DEATHS IN US, CDC SITE

Coronavirus Vaccine Tracker – The New York Times

Categories: Vaccine

2 replies

  1. Moderna Inc. MRNA +5.53% said Wednesday its experimental coronavirus vaccine induced immune responses in people aged 56 years and older that were comparable to those seen in younger adults in a small study, a promising sign for a vulnerable age group.

    Older adults are at higher risk of hospitalization and death from Covid-19 than younger people. While Moderna and other companies are racing to develop vaccines to protect people from the new coronavirus, some experts have been concerned that vaccines won’t offer as much protection in older adults.

    The immune system generally weakens with age, which can make it harder for a vaccine to induce a sufficient immune response against disease.

    https://www.wsj.com/articles/moderna-says-covid-19-vaccine-shows-signs-of-working-in-older-adults-11598452800?mod=hp_lead_pos6

  2. Moderna Inc (NASDAQ: MRNA) said it’s in discussions with the Ministry of Health, Labour and Welfare of Japan to potentially purchase 40 million or more doses of mRNA-1273, its vaccine candidate against COVID-19, to support Japan’s aim of providing vaccines to the public as soon as possible.

    The agreement being negotiated calls for Moderna supplying the vaccine and Japanese drugmaker Takeda Pharmaceutical Co., Ltd. (NYSE: TAK) distributing it, beginning in the first half of 2021, contingent on the vaccine getting the regulatory nod.

    https://finance.yahoo.com/news/daily-biotech-pulse-moderna-japanese-122604557.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.